Breast cancers possess fundamentally altered metabolism that fuels their pathogenicity. While many metabolic drivers of breast cancers have been identified, the metabolic pathways that mediate breast cancer malignancy and poor prognosis are less well understood. Here, we used a reactivity-based chemoproteomic platform to profile metabolic enzymes that are enriched in breast cancer cell types linked to poor prognosis, including triple-negative breast cancer (TNBC) cells and breast cancer cells that have undergone an epithelial-mesenchymal transition-like state of heightened malignancy. We identified glutathione S-transferase Pi 1 (GSTP1) as a novel TNBC target that controls cancer pathogenicity by regulating glycolytic and lipid metabolism, energetics, and oncogenic signaling pathways through a protein interaction that activates glyceraldehyde-3-phosphate dehydrogenase activity. We show that genetic or pharmacological inactivation of GSTP1 impairs cell survival and tumorigenesis in TNBC cells. We put forth GSTP1 inhibitors as a novel therapeutic strategy for combatting TNBCs through impairing key cancer metabolism and signaling pathways.
In Brief
Using a reactivity-based chemoproteomic platform, Louie et al. have identified GSTP1 as a triple-negative breast cancer target that, when inhibited, impairs breast cancer pathogenicity through inhibiting GAPDH activity and downstream metabolism and signaling pathways.
INTRODUCTION
Breast cancers possess fundamentally altered metabolism that drives their pathogenic features. Since Otto Warburg's seminal discovery in the 1920s that cancer cells have heightened glucose uptake and aerobic glycolysis, recent studies have identified many other biochemical alterations in cancer cells, including heightened glutamine-dependent anaplerosis and de novo lipid biosynthesis, which serve as metabolic platforms for breast cancer cells to generate biomass for cell division and metabolites that modulate cancer cell signaling, epigenetics, and pathogenicity (Benjamin et al., 2012; Cantor and Sabatini, 2012; Pavlova and Thompson, 2016) . While targeting dysregulated metabolism is a promising strategy for breast cancer treatment, the metabolic pathways that drive pathogenicity in breast cancer subtypes that are correlated with heightened malignancy and poor prognosis remain poorly understood.
Mortality from breast cancer is almost always attributed to metastatic spread of the disease to other organs, thus precluding resection as a treatment method. Unfortunately, conventional chemotherapy fails to eradicate most human cancers, including aggressive breast cancers. Studies over the past decade have uncovered certain breast cancer types and cell types that are associated with poor prognosis, such as estrogen/progesterone/HER2 receptor-negative (triple-negative) breast cancers (TNBCs) or cancer stem/precursor cells that possess self-renewing and tumor-initiating capabilities, epithelial-to-mesenchymal transition (EMT), poor prognosis, and chemotherapy resistance within breast tumors (Dawson et al., 2009; Dietze et al., 2015; Polyak and Weinberg, 2009 ). While eliminating these breast cancer types is critical in combatting breast cancer, there are currently few to no therapies that target this malignant population of breast cancer cells.
In this study, we used a reactivity-based chemoproteomic platform to identify metabolic enzymes that are heightened in TNBC cells or upon induction of an EMT-like programming of heightened malignancy in breast cancer cells. Through this profiling effort, we identified glutathione S-transferase Pi 1 (GSTP1) as a critical metabolic driver that is heightened specifically in TNBCs to control multiple critical nodes in cancer metabolism and signaling pathways to drive breast cancer pathogenicity.
RESULTS

Profiling Dysregulated Metabolic Enzymes in TNBC Cells and CDH1 Knockdown Breast Cancer Cells
To identify metabolic drivers of breast cancer pathogenicity in aggressive breast cancer cell types associated with malignancy and poor prognosis, we used a reactivity-based chemical proteomic strategy to map cysteine and lysine reactivity in TNBC cells and breast cancer cells with EMT-like features ( Figure 1 ; Table  S1 ). Both TNBC cells and breast cancer cells that have undergone EMT have been linked to heightened aggressiveness and poor prognosis. Specifically, we wanted to (1) identify TNBCspecific metabolic enzyme targets by comparing a panel of four non-TNBC and five TNBC cell lines, and (2) identify upregulated enzyme targets in MCF7 breast cancer cells upon knockdown of CDH1, a critical mediator of EMT and cell-cell adhesion. We knocked down CDH1 in MCF7 cells with short-hairpin (sh) oligonucleotides (shCDH1 cells) to induce an EMT-like state. MCF7  T47D  ZR751  MDA-MB-361   231MFP  HCC1143  HCC38  HCC70  MDA-MB-468   non-TNBC  TNBC   LDHB  PFKM  AGPS  DLAT  PSAT1  GLS  ALDH2  CBR1  ALDH1A2  TXNRD2  GSTP1  PLCG1  PPAT  CTPS  SOAT1  ADSL  PFAS  ACADSB  ACLY  SCP2  GSPT1  ESD  PRPSAP2  CKB  PHGDH  ALDH1B1  ASNS  SORD  ALDH7A1  OAT  ACAT1  PAFAH1B1  GLRX3  SHMT2  PDHA1  PYCR2  PGLS  PCMT1  GOT2  PDHB  USP9X  IMPDH2  MTHFD1L  ACAT2  CMAS  ALDH18A1  GSTM3  ALDH9A1  PAPSS1  MDH1  ACAA2  GMPS  CKMT1A  FH  MTHFD1  SDHA  MDH2  GSTO1  OXCT1  TKT  ASMTL  HADHA  HSDL2  ACO2  HSD17B10  PRDX1  ALDH5A1  PTPLAD1  TXNDC5  GFPT1  PTGES2  GAPDH  ECHS1  PGD  ALDH7A1  NAT10  RPN1  HMGCS1  MCCC2  HADHB  FASN  PFKP  IDH1  ACAD9 GSTP1  ALDH1A3  PSAT1  ASS1  ENO3  AGPS  ACAA2  CTH  SOD2   PYGL  ALDH1L2  MTHFD2  PLOD1  GNE  NCEH1  ACSL5  CTPS  LDLR   ACOT9  ACP6   PNPLA6   DPYD  ALDH3A2   ACOT7  SAMHD1   PLOD3  PSPH  SGPL1  ADH5  GCAT  GMDS  PGM1  PLD3  AK2  ALDH1A1  CPS1  DHCR7  ENPP1  GYS1  PLAA  TYMP  ABHD12  CBS  GSTK1  OAS3  PNPT1  RDH11  ADSL  BCKDK  C11orf54  DPYSL2  GSTM1  LDHAL6B  MGST3  PNP  ACSS2  A G PAT 9   AKR1B10   AKR1B1   AKR1C3  CA2  CPPED1  DEGS1  DHPS  DHRS7  ETFDH  FAR1  GALE  GCLM  GGCX  GNPTAB  IDI1  LPCAT2  MCAT  ME2  MPI  MTAP  NMT1  P4HA1  P4HA2  PCYT2  PDPR  PIP4K2C  PLCG2  UGCG  MAOA  GLS  ACAT2  PC  ALDH1B1  OAT  ACSL4  NAMPT  IDH3B  PHGDH  GSTO1  C21orf33  PGLS  OGT  ACADM  CBR1  NSDHL  MTHFD1L  ADK  PYGB  ADSS  SUCLG2  GART  UGP2  PLOD2  HMGCL  ACAA1  ACSL3  PYGM  PFKP  DLAT  ACOT8  SCP2  ECHS1  OXCT1  LSS  LDHB  ILVBL  SDHA  CMAS  SDHB  ACAD9  PPA1  GLUD1  HPRT1  ENO2  SHMT2  DHCR24  DCI  FDPS  MDH1  HSD17B4  MAT2A  ECH1  SUCLG1  ENO1  NNT  NDUFA9  A G PAT 1  FLAD1  TALDO1  OGDH  HADHA  GPD2  ACO2  PGK1  DLD  MTHFD1  GFPT1  HK2  GANAB  ACADVL  LDHA  ACLY  PDHA1  TKT  ALG2  GLO1  GOT2  IMPDH2  ACACA  ALDH18A1  ACAT1  L2HGDH  PKLR  PDXK  CS  HK1  PTGES2  PCK2  MCCC1  MDH2  GLUD2  PFKL  PKM2  HIBADH  HSDL2  IDH3A  PGD  HMGCS1  CCBL2  C12orf5  ESD  GPX1  GSTZ1  NDUFV1  PAFAH1B3  UGGT1  PDHB  HADHB  AHCY  ACSL1  ALDH7A1  GPI  IDH1  GMPS  NDUFS1  HMOX2  MVK  ALDOA  DHTKD1  HADH  PDXDC1  ACO1  GAPDH  PGAM1  ACSF2  SACM1L  GOT1  MAT2B  NDUFS2  PFKL  FAH  LTA 4 H  PFKM  HSD17B10  SHMT1  ACOX1  ISYNA1  IVD  MPST  PCYOX1  CKMT1A  ALDOC  ALDH2  NANS  COMT  ALDH5A1  BCKDHA  NME1  IDH2  FDXR  FASN  NQO1  SORD  ALDH9A1  G6PD  ALDH16A1  GRHPR  SPTLC2  CKB  DECR1  CPT1A  AKR1A1  PTPLAD1  ALDH6A1  PAPSS2  GSR  UGDH  GSTM3  LPCAT1  COASY  BLVRA  MCCC2  FBP1  ABAT  ACOT2  ACOX3  AKR1C1  AKR7A2  ALDH4A1  ALOX15B  APRT  BCKDHB  BDH1  BLMH  CMBL  COMTD1  DBT  DCXR  DERA  DHRS2  DLST  DUT  EPHX1  FAHD1  FAHD2A  FDFT1  FTO  GALK1  GALNT7  GAMT  GAMT  GANAB  GGH  GNPNAT1  GSS  HEXA  HMGCS2  INPP4B  MBOAT7  MGST1  MMAB  MTHFD1  NDUFB8  NDUFS3  NME3  OGFR  PCMT1  PECI  PFAS  PGK2  PGP  PI4KA  PLCB3  PNPLA2  PPA2  PRPS2  PRPSAP1  PTGES3  PTGES3  PTGR2  QDPR  SLC27A2  SULT1A1 2,000 1,500 1,000 These cells show upregulation of the mesenchymal marker vimentin and concordant increases in serum-free cell survival, proliferation, and migration ( Figure S1 ), consistent with EMTlike characteristics.
MCF10A
We labeled cell lysates from these two breast cancer models with previously validated lysine-reactive dichlorotriazine-alkyne or cysteine-reactive iodoacetamide-alkyne reactivity-based probes to tag proteins bearing functional lysines or cysteines, respectively, for subsequent attachment of a biotin handle by click chemistry, enrichment, and analysis by mass spectrometry (MS), using an adapted method established by Weerapana and co-workers (Figures 1A and 1B ; Table S1 ) (Shannon et al., 2014; Weerapana et al., 2010) . We chose to profile cysteine and lysine reactivity in this study, since these amino acids are important mediators of enzyme activity or function through nucleophilic and redox catalysis, allosteric regulation, metal binding, and structural stabilization across a wide range of protein classes (Pace and Weerapana, 2013; Shannon and Weerapana, 2015) . Upon proteomic analysis of probe-enriched protein targets, we filtered these proteins for metabolic enzyme targets that were significantly upregulated (p < 0.01, >5-fold) in TNBC cells or shCDH1 MCF7 cells compared with non-TNBC or shControl counterparts, respectively (Figures 1C and 1D ; Table S1 ). GSTP1 was the most significantly upregulated target in TNBC cells that was also significantly heightened in shCDH1 cells, so we focused on investigating the pathogenic role of this target in breast cancer ( Figures 1C and 1D ).
Many human cancers, including breast, lung, colon, and ovarian cancers, have been shown to express high levels of GSTP1, and its expression has been correlated with both disease progression and resistance to chemotherapeutic drugs (Laborde, 2010) . GSTP1 inhibitors have been studied in the context of cancer for many years as adjuvant therapies with chemotherapy agents to prevent their detoxification by cancer cells, with the aim of improving chemotherapy efficacy (Tew and Townsend, 2011; Townsend and Tew, 2003) . Yet the majority of chemotherapeutic drugs have a relatively weak affinity for GSTP1 compared with other GST enzymes. This discrepancy between expression of GSTP1 and its correlation with the development of multidrug resistance suggests additional roles for GSTP1 on influencing metabolic and signaling pathways in cancer cells (Laborde, 2010) . GSTP1 inhibitors have not yet been investigated for their potential as stand-alone therapies toward thwarting breast cancer. We thus focused our attention on further investigating the role of GSTP1 in driving breast cancer pathogenicity.
GSTP1 Is a TNBC-Specific Target
We next investigated the expression pattern of GSTP1 in different types of breast cancer cell lines and primary human breast tumors. Interestingly, we show that GSTP1 is not expressed in any of the non-TNBC cells (MCF7, T47D, ZR751, and MDA-MB-361), but is highly expressed across all of the TNBC cells (231MFP, HCC1143, HCC38, HCC70, and MDA-MB-468) (Figures 1E and 1F) , shown both by dichlorotriazine-alkyne reactivity and western blotting. We also show that GSTP1 expression is significantly heightened in TNBC compared with receptor-positive primary human breast tumors ( Figure 1G ). Overall, our data indicate that GSTP1 may represent a TNBC-specific target.
Genetic or Pharmacological Inactivation of GSTP1 Impairs TNBC Pathogenicity To investigate the role of GSTP1 in TNBC pathogenicity, we generated two knockdown lines of GSTP1 in TNBC 231MFP cells (shGSTP1-1 and shGSTP1-2) ( Figure 2A ). We showed that GSTP1 knockdown impairs serum-free cell survival in 231MFP cells without affecting cell proliferation ( Figure 2B ). GSTP1 knockdown also impaired in vivo 231MFP breast tumor xenograft growth in immune-deficient mice ( Figure 2C ).
Intrigued by these results, we next tested whether pharmacological inhibition of GSTP1 with a highly selective GSTP1 inhibitor LAS17 also impaired breast cancer pathogenicity. LAS17 was recently developed as a highly potent, selective, and irreversible dichlorotriazine GSTP1 inhibitor that targets an active-site tyrosine ( Figure 2D ) (Crawford and Weerapana, 2016) . In addition to its property as a GSTP1 inhibitor, LAS17 also bears a bioorthogonal alkyne handle, which can be coupled with coppercatalyzed click chemistry (Martell and Weerapana, 2014) to append a fluorophore-azide or biotin-azide analytical handle for subsequent fluorescent or proteomics-based detection of GSTP1, respectively ( Figures 2D and 2E ). LAS17 inhibits GSTP1 activity in vitro with a 50% inhibitory concentration (IC 50 ) value of 0.5 mM ( Figure 2F ).
LAS17 treatment in 231MFP breast cancer cells recapitulated the serum-free cell survival impairments observed with genetic inactivation of GSTP1 ( Figure 2G ). Daily administration of LAS17 (20 mg/kg intraperitoneally, once per day) significantly impaired 231MFP breast tumor xenograft growth in immunedeficient mice when treatment was initiated 2 days after subcutaneous injection of cells, and LAS17 even slowed tumor growth when initiated 16 days after tumor implantation ( Figure 2H ), with no observable toxicity and no weight change ( Figure S2A ). LAS17 had no effect on serum-free survival of shControl MCF7 non-TNBC cells that do not express GSTP1, but significantly impaired the survival of shCDH1 MCF7 breast cancer cells (Figure 2I) . While GSTP1 inhibition selectively impaired survival in shCDH1 cells, LAS17 treatment in shCDH1 cells did not rescue vimentin expression or impair proliferation, indicating that GSTP1 is not a critical driver of the EMT process (data not shown). LAS17 treatment also impaired serum-free cell survival in additional TNBC lines HCC38, HCC70, and HCC1143 (Figure 2J) . We also show that GSTP1 knockdown in HCC38 cells impairs cell survival (Figures S2B and S2C) . We thus show that pharmacological GSTP1 inactivation impairs breast cancer pathogenicity in culture and in vivo in a seemingly TNBC-specific manner, suggesting that GSTP1 inhibitors may be promising therapeutics for treating TNBCs.
(F) GSTP1 expression was measured across a panel of MCF10A non-transformed mammary epithelial cells, non-TNBC, and TNBC cell lines by western blotting. Western blotting image shown is representative of n = 3/group. GSTP1 expression was normalized to actin loading control and quantified by densitometry. (G) GSTP1 expression in receptor-positive and TNBC primary human breast tumors from The Cancer Genome Atlas (TCGA) database. FDR, false-discovery rate. Data in (C-G) are presented as mean ± SEM, n = 3-5/group. Significance is presented as *p < 0.05 compared with non-TNBC or shControl cells. Detailed data from the chemoproteomic study in (A-D) are provided in Table S1 . Characterization of shCDH1 cells is shown in Figure S1 .
Functional Metabolomic Profiling Reveals GSTP1 Control Over Glycolytic Metabolism, Energetics, and Macromolecular Building Blocks
We next wanted to understand the mechanisms through which GSTP1 was controlling breast cancer pathogenicity. Previous studies have shown that GSTP1 may directly affect cancer pathogenicity through protein-protein interactions with the MAPK family protein JNK, leading to JNK phosphorylation and activation (Tew and Townsend, 2011; Townsend and Tew, 2003) . However, GSTP1 genetic or pharmacological inactivation (A) GSTP1 was knocked down in 231MFP TNBC cells using two independent shRNA, and expression was confirmed by both qPCR and western blotting. Western blotting image is representative of n = 3/group and protein expression was quantified by densitometry. (B) GSTP1 knockdown in 231MFP cells shows impaired serum-free cell survival, with no change in cell proliferation 48 hr after seeding. Survival and proliferation were assessed using Hoechst stain. (C) shGSTP1 231MFP cells show impaired tumor growth in SCID mice compared with shControl cells. (D) Selective and irreversible dichlorotriazine GSTP1 inhibitor LAS17 bearing a dichlorotriazine electrophile, GSTP1 binding group, and an alkyne handle for subsequent click chemistry. (E) LAS17 labeling of shControl and shCDH1 MCF7 cells showing heightened GSTP1 in shCDH1 cells. Cell lysates were labeled with LAS17 for 30 min prior to click chemistry with rhodamine-azide. Proteomes were separated on SDS-PAGE and visualized by in-gel fluorescence. (F) LAS17 inhibits GSTP1 activity with a 50% inhibitory concentration (IC50) of 0.5 mM. GSTP1 activity was assessed by pre-incubating vehicle DMSO or LAS17 with pure GSTP1 protein for 30 min prior to measuring the rate of conjugation of glutathione to CDNB and quantifying the rate of increase in the absorption of the reaction product, glutathione-DNB conjugate. (G) Serum-free survival 48 hr after seeding in 231MFP cells treated with DMSO vehicle or LAS17 (10 mM), determined by Hoechst staining. (H) 231MFP tumor xenograft growth in SCID mice upon once-per-day daily treatment with vehicle (18:1:1 PBS/ethanol/PEG 40) or LAS17 (20 mg/kg, intraperitoneally) initiated either 2 or 16 days after subcutaneous injection of 2 3 10 6 231MFP cells.
(I) Serum-free cell survival in shControl and shCDH1 MCF7 cells treated with DMSO vehicle or LAS17 treatment (10 mM) in shControl and shCDH1 MCF7 cells, determined by WST-1 assay.
(J) Serum-free cell survival 48 hr after seeding in HCC38, HCC70, and HCC1143 cells treated with DMSO vehicle or LAS17 (10 mM), determined by Hoechst staining. Data in (A-C), (F), and (G-J) are presented as mean ± SEM, n = 3/group in (A), n = 5/group in (B), n = 8/group in (C), n = 3/group in (F), n = 5/group in (G), n = 8/group in (H), and n = 5/group in (I) and (J). Significance is presented as *p < 0.05 compared with shControl and #p < 0.05 compared to shCDH1 vehicle-treated control. Body weights and further effects of GSTP1 inhibition upon TNBC pathogenicity are shown in Figure S2 .
did not lead to JNK activation compared with treatment with the JNK activator anisomycin in 231MFP cells ( Figure S3A ). We also postulated that GSTP1 could modulate glutathione levels and oxidative stress to cause cell-survival impairments. However, genetic or pharmacological inactivation of GSTP1 did not change oxidative stress levels or reduced oxidized glutathione (GSH/GSSG) ratios under both basal and menadione-induced oxidative stress conditions compared with controls ( Figures  S3B-S3D ).
To identify alternative mechanisms, we next performed functional metabolomic profiling to comprehensively map metabolic alterations conferred by genetic or pharmacological inactivation of GSTP1 in 231MFP breast cancer cells ( Figures 3A-3C and S4A-S4F; Table S2 ). We used a targeted single-reaction monitoring (SRM)-based liquid chromatography-tandem MS (LC-MS/MS) approach to comparatively measure the levels of $200 metabolites encompassing glycolytic, tricarboxylic acid (TCA) cycle, amino acid, nucleotide, and lipid metabolism. We also used an untargeted LC-MS approach in which we collected mass spectra from mass-to-charge ratios (m/z) of 100-1,200 and analyzed the resulting features by XCMSOnline (Gowda et al., 2014) to identify metabolites that were altered upon GSTP1 inactivation. We subsequently analyzed any changing m/z by METLIN to identify candidate metabolites, used targeted SRMbased LC-MS/MS to quantify the levels of these metabolites, and added these data to our total targeted analyses. Through these approaches we identified several metabolites that were commonly changing between both shGSTP1 231MFP lines, including lowered levels of lactic acid, ATP, nucleotides, diacylated phospholipids, and alkylacyl ether lipids, and increased levels of acyl carnitines (ACs), ceramides, and lysophospholipids (Figures 3A-3C ; Table S2 ). LAS17 treatment in 231MFP cells also showed reduced levels of ATP, lactic acid, purine nucleotides, diacylated phospholipids, and alkylacyl ether lipids, and increased levels of ACs, ceramides, and lysophospholipids (Figures S4B-S4F; Table S2 ). While there were many metabolomic changes that were unique to either shGSTP1 or LAS17 treatment, we attributed these differences to metabolic alterations that may manifest under chronic and stable knockdown versus acute inhibition of GSTP1. Nonetheless, between the common changes and even the uncommon changes in metabolite levels, we were able to identify overlapping metabolic pathways that were altered upon GSTP1 inhibition.
Upon mapping the observed metabolomic changes to metabolic pathway maps, our data suggested that GSTP1 inactivation led to impairments in glycolytic metabolism, leading to reduced lactic acid and ATP levels as well as reductions in the levels of macromolecular building blocks, including purine nucleotides, fatty acids, diacylphospholipids, and alkylacyl ether lipids ( Figure 3C ). Consistent with this premise, we observed significant and time-dependent reductions in lactic acid secretion or glucose consumption upon GSTP1 knockdown in shGSTP1 cells or upon LAS17 treatment in 231MFP cells, compared with shControl or vehicle-treated controls, respectively ( Figures 3D  and S4E ), indicating reduced glycolytic metabolism.
GSTP1 Inhibition Impairs Oncogenic Signaling Pathways
The reduced levels of ATP and increased levels of ACs (C18:0 AC), a product of carnitine palmitoyltransferase 1 (CPT1), suggested heightened phosphorylation and activity of AMP kinase (AMPK) and also phosphorylation and inhibition of the downstream substrate acetyl coenzyme A (CoA) carboxylase (ACC). Inhibited ACC would presumably lead to decreased malonyl CoA levels and derepression of CPT1, and thus the observed increase in AC levels. We show that GSTP1 knockdown in both shGSTP1 cells and LAS17 treatment in 231MFP cells result in increased levels of phosphorylated AMPK and ACC ( Figures  4A and 4B) .
Activation of AMPK has been previously shown to impair breast cancer pathogenicity, partly by inhibiting mammalian target of rapamycin (mTOR) activity and downstream protein synthesis (Dowling et al., 2007) . Consistent with the role of AMPK in driving the GSTP1 inhibition-mediated breast cancer pathogenicity impairments, we show that the cell-survival impairments conferred by GSTP1 knockdown are partially rescued upon treatment with the AMPK inhibitor dorsomorphin (Figure 4C) . We also show that the levels of phosphorylated S6, downstream of mTOR and S6 kinase, are lower in shGSTP1-and LAS17-treated 231MFP breast cancer cells compared with shControl or vehicle-treated control cells, respectively (Figure 4D) . Consistent with the role of impaired mTOR signaling in GSTP1 inhibition-mediated survival defects, treatment of 231MFP cells with the mTOR inhibitor Torin 1 alone causes survival impairments, but co-treatment of 231MFP cells with Torin 1 and LAS17 does not cause additional survival impairments beyond those observed with LAS17 treatment alone ( Figure 4E ).
GSTP1 Interacts with and Activates GAPDH Activity to Influence Glycolytic Metabolism
We next wanted to investigate the mechanism through which GSTP1 controlled glycolytic metabolism. GSTP1 has been previously shown to control signaling pathways through proteinprotein interactions. We thus generated a 231MFP cell line stably overexpressing a FLAG-tagged GSTP1 and performed a pulldown study to identify GSTP1 interacting proteins through proteomic profiling (Figures S5A-S5C ). We found that anti-FLAG pulldown in GSTP1-FLAG-overexpressing cell lysates significantly enriched seven proteins compared with mockinfected control cell lysates ( Figure S5C ). Among these seven proteins was glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was significantly enriched in GSTP1-FLAG-expressing cells compared with mock-infected control 231MFP cells ( Figure 5A ). While we could not confirm this GSTP1 interaction with endogenous GAPDH, we showed that addition of exogenous pure and active GAPDH enzyme could lead to enrichment of GAPDH upon anti-FLAG pulldown in GSTP1-FLAG-overexpressing cell lysates compared with mock-infected control lysates ( Figure 5B ).
We thus postulated that GSTP1 may interact with GAPDH to influence its activity. Consistent with this hypothesis, we show that GSTP1 greatly activates GAPDH activity in vitro ( Figure 5C ). This activation in GAPDH activity was independent of glutathione (GSH) or oxidized glutathione (GSSG), indicating that this activity was not due to glutathione conjugation of a small-molecule metabolite or glutathionylation of GAPDH ( Figure S5D ). LAS17 itself does not inhibit GAPDH activity ( Figure S5E ). This GSTP1-induced GAPDH activity was, however, partially suppressed by LAS17 pre-treatment, indicating that LAS17 binding to GSTP1 
(legend continued on next page)
at least partially disrupts the GSTP1-GAPDH protein-protein interaction ( Figure 5C ). To complement our steady-state metabolomic profiling data and further confirm our proposed mechanism that GSTP1 inhibition indirectly inhibits glycolysis through impairing GAPDH activity, we performed Figures 5D and 5E ). Overall, these data are consistent with an inhibition of GAPDH activity from GSTP1 inhibition. [
13 C]
Fructose-1,6-bisphosphate levels were reduced, indicating that GSTP1 may potentially also affect additional nodes in glycolysis.
We also show that the impaired glycolytic metabolism downstream of GAPDH also affects other related downstream pathways, including lowered levels of Figures 5D  and 5E ), and the reductions in the levels of phospholipid and ether lipid levels ( Figures 3B, 3C , and 5E). Our steady-state metabolomic data also showed reduced levels of purine nucleotides such as adenine and guanine, which is counter-indicative to heightened PPP observed from our tracing studies. However, detailed tracing analysis shows that the levels of [ 13 C]adenine AMP (m+7), derived from isotopic incorporation of glucose into PPP metabolites (m+5) and glycine (m+2), are lowered, whereas levels of [ 13 C]AMP (m+5), derived only from glucose incorporation into PPP metabolites, are elevated ( Figure 5D ). These data indicate that the observed reductions in nucleotide levels are likely due to the reduction in glycine necessary for de novo synthesis of purines ( Figures 3B, 3C, 5D , and 5E).
(D) Lactic acid secretion into the media in shControl and shGSTP1-1 231MFP cells or DMSO vehicle-treated or LAS17-treated (10 mM) 231MFP cells. Lactic acid was measured using a lactic acid measurement kit. Data in (B) and (D) are presented as mean ± SEM, n = 5/group. Significance in (D) is presented as *p < 0.05 compared with shControl or DMSO vehicle-treated controls. Detailed data, explanation of abbreviations, and SRM transitions are provided in Table S2 . Effect of GSTP1 inhibition on JNK signaling and oxidative stress is shown in Figure S3 , and metabolic characterization of LAS17-treated 231MFP cells is shown in Figure S4 . While GSTP1 expression is heightened in TNBC compared with non-TNBC cells, we also showed that GSTP1 is expressed in non-transformed MCF10A mammary epithelial cells. We find that GSTP1 inhibition in MCF10A cells does not impair cell survival compared with significantly impaired survival in 231MFP cells ( Figure S5F ). Interestingly, LAS17 treatment in MCF10A cells also impairs lactic acid secretion, indicating that glycolytic metabolism may also be impaired in these cells ( Figure S5G ). We postulated that TNBC cells may be more addicted to glycolytic metabolism compared with MCF10A cells. Consistent with this premise, 231MFP cell survival is significantly impaired by the glycolytic hexokinase inhibitor 2-deoxyglucose (2DG) to a degree comparable to that of LAS17, but MCF10A cells show no survival impairment upon 2DG treatment ( Figure S5H ).
DISCUSSION
Taken together, our data point to GSTP1 as a novel TNBC target that, when inactivated, impairs glycolytic metabolism through a unique mechanism of disrupting GSTP1-induced activation of GAPDH, leading to lower levels of macromolecular building blocks (e.g., lipids and nucleotides) and ATP levels. This reduction in energy levels in turn also leads to impaired oncogenic GAPDH(input) e G F P G S T P 1 -F L A G e G F P G S T P 1 -F L A G Figure 5 . GSTP1 Interacts with and Activates GAPDH Activity to Influence Glycolytic Metabolism (A) We generated stable GFP-expressing control and GSTP1-FLAG-overexpressing 231MFP cells to identify GSTP1 interaction partners. Upon anti-FLAG pulldown of GFP-expressing control (EGFP) or GSTP1-FLAG-overexpressing 231MFP lysates and subsequent proteomic analysis of pulled-down proteins, we found enrichment of GSTP1 and GAPDH.
(B) This GSTP1-GAPDH interaction was confirmed by incubation of pure and active GAPDH enzyme with GFP-expressing or GSTP1-FLAG-overexpressing 231MFP cell lysates, subsequent anti-FLAG pulldown, and western blotting of GAPDH. Shown are GAPDH blots for input and immunoprecipitation fractions. (C) Effect of co-incubating pure and active GSTP1 and GAPDH proteins individually or together on GAPDH activity, assessed by a GAPDH activity assay measuring NADH, a by-product of the conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate. GAPDH was treated with DMSO vehicle and GAPDH + GSTP1 was treated with DMSO vehicle or LAS17 (10 mM) 30 min prior to assessment of GAPDH activity. (E) Model of mechanisms underlying GSTP1 control over breast cancer pathogenicity, based on steady-state metabolomics, isotopic tracing, and western blotting data. Data in (A) and (D) are presented as mean ± SEM, n = 3-5/group. Significance is presented as *p < 0.05 compared with EGFP or DMSO vehicle-treated controls, respectively. Data in (C) are presented as mean ± SEM, n = 3/group. Significance in (C) is presented as *p < 0.05 compared with GAPDH only and # p < 0.05 compared with the GAPDH and GSTP1 group. Further characterization of GSTP1 protein interactions and the role of GSTP1 in MCF10A cells are described in Figure S5 .
signaling through activation of AMPK and inhibition of mTOR signaling ( Figure 5E ). While our interpretations presented here are consistent with the metabolomic and signaling changes that we observe with GSTP1 inactivation in breast cancer cells, we expect that there are also additional mechanisms involved that may arise from the metabolomic changes we observed. For example, we showed increased levels of ACs with GSTP1 inhibition, which we presume to be downstream of ACC inhibition and derepression of CPT1. These results could indicate that fatty acid b-oxidation pathways may be activated upon GSTP1 inactivation. While we did not observe rescue of cell-survival impairments with the CPT1 inhibitor etomoxir (data not shown), the observed increase in AC levels may play a role in other aspects of GSTP1-mediated effects (Carracedo et al., 2013) .
GSTP1 has also been linked to many other functions in cancer and other human pathologies and even in drug addiction. Beyond glutathionylation and detoxification functions, GSTP1 has been shown to possess chaperone functions, regulation of nitric oxide pathways, and control over various kinase signaling pathways (Zhang et al., 2014) . For example, GSTP1 inhibits JNK signaling and prevents downstream transcriptional activation of cell-stress pathways. Under cellular stress conditions whereby reactive oxygen stress is heightened, GSTP1 has been shown to dimerize into larger aggregates and preclude binding to JNK, enabling JNK activation. In the context of hematopoiesis, GSTP1 inhibition has been shown to play a cytoprotective role in both erythroid and lymphoid cells, and the GSTP1 inhibitor ezatiostat has been shown to be clinically effective for myelodysplastic syndrome (Mahadevan and Sutton, 2015; Zhang et al., 2014) . While we report here that GSTP1 inhibition does not activate JNK signaling in our TNBC cells, GSTP1 may still directly regulate other signaling pathways through protein interactions or glutathionylation-mediated pathways (Zhang et al., 2014) .
We also acknowledge that the apparent activation of GAPDH activity by GSTP1 is only modestly reduced upon LAS17 treatment, indicating that there may be additional complexities involved in the mechanism underlying the GSTP1 induction of GAPDH activity. While our isotopic tracing data clearly indicate that GSTP1 inhibition leads to an impairment in the ATP-generating steps of glycolysis downstream of GAPDH, we do not yet understand the mechanism through which this occurs. GAPDH activity is dependent on a highly reactive catalytic cysteine that coordinates the interconversion between glyceraldehyde-3-phosphate into 1,3-bisphosphoglycerate and is particularly sensitive to oxidation by agents such as hydrogen peroxide or other oxidants that can inhibit GAPDH activity (Hildebrandt et al., 2015) . Reports have also shown that GAPDH can even be inhibited by its reactive 1,3-bisphosphoglycerate product on a hyperreactive and functional lysine to inhibit its activity (Moellering and Cravatt, 2013) . It would be of future interest to investigate whether GSTP1 interacts with GAPDH to protect hyperreactive sites from being adducted and inhibited. GSTP1 has also been shown to glutathionylate cysteines on proteins to post-translationally regulate protein structure and function and protect proteins from degradation from sulfhydryl overoxidation or proteolysis (Grek et al., 2013 ). While we were not able to detect GAPDH glutathionylation by GSTP1 and the activation of GAPDH by GSTP1 was independent of GSSG and GSH, it may still be possible that GAPDH activity and glycolytic metabolism may be regulated by GSTP1-mediated glutathionylation. Furthermore, while GAPDH is not generally considered to be a rate-limiting step of glycolysis, a recent study has shown that GAPDH is rate limiting in cancer cells that possess aerobic glycolysis (Hildebrandt et al., 2015; Moellering and Cravatt, 2013; Shestov et al., 2014) . Our studies with GSTP1 provide additional support for how GAPDH may act as a major regulatory hub for TNBC glycolytic activity.
We show that pharmacological inactivation of GSTP1 over a sustained period does not show any observable toxicity, and not only prevents breast tumor growth but even slows established breast tumor growth in mice. A highly potent GSTP1 inhibitor, ezatiostat (developed by Telik Inc.) has passed phase II clinical trials in patients for the treatment of myelodysplastic syndrome, indicating that GSTP1 inhibitors are likely to be well tolerated in humans (Mahadevan and Sutton, 2015) . Beyond the many previously reported biochemical and therapeutic roles of GSTP1 (Grek et al., 2013; Tew and Townsend, 2011; Townsend and Tew, 2003) , our study suggests that GSTP1 inhibitors may also be promising stand-alone therapeutics for TNBCs. Our study also underscores the utility of using reactivity-based chemoproteomic platforms coupled with functional metabolomic approaches to identify novel metabolic drivers and pathways underlying breast cancer malignancy.
SIGNIFICANCE
TNBCs and stem-like breast cancers that have undergone EMT have been linked to breast cancer malignancy and poor prognosis. While these breast cancer cell types are particularly dangerous, there are few to no therapeutic strategies that specifically target these types of cells. Here, we have used chemoproteomic profiling platforms to identify GSTP1 as a novel potential therapeutic target for TNBCs. We show that GSTP1 interacts with GAPDH to activate its activity and that GSTP1 inactivation impairs glycolytic metabolism after the GAPDH step in glycolysis to impair ATP generation, nucleotide and fatty acid metabolism, and oncogenic signaling pathways. We show that GSTP1 inhibitors show selective killing of TNBC cells over non-TNBC or non-transformed mammary epithelial cells and that longterm GSTP1 inhibition in mice does not cause overt toxicity or weight loss. Taking our findings together, we show that GSTP1 inhibitors may potentially be novel therapeutic agents to specifically target TNBCs.
EXPERIMENTAL PROCEDURES Chemicals
The AMPK inhibitor dorsomorphin dihydrochloride and the mTOR inhibitor Torin 1 were obtained from Tocris. LAS17 was synthesized as described previously (Crawford and Weerapana, 2016) . Menadione was obtained from Spectrum Chemical.
Cell Culture
The 231MFP cells were obtained from Prof. Benjamin Cravatt and were generated from explanted tumor xenografts of MDA-MB-231 cells. MCF7, MCF10A, T47D, ZR751, MDA-MB-361, HCC1143, HCC38, HCC70, MDA-MB-468, and HEK293T cells were obtained from the American Type Culture Collection. HEK293T cells were cultured in DMEM containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37 C with 5% CO 2 . 231MFP, MDA-MB-361, and MDA-MB 468 cells were cultured in L15 medium containing 10% FBS and maintained at 37 C with 0% CO 2 . MCF10A cells were cultured in DMEM/ F12K medium containing 5% horse serum, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 10 ng/ml insulin, and 500 ng/ml hydrocortisone, and maintained at 37 C with 5% CO 2 . MCF7, T47D, ZR751, HCC1143, HCC38, and HCC70 cells were cultured in RPMI medium containing 10% FBS and maintained at 37 C with 5% CO 2 .
Gene Expression by qPCR qPCR was performed using the manufacturer's protocol for Fisher Maxima SYBR Green with 10 mM primer concentrations or for Bio-Rad SsoAdvanced Universal Probes Supermix. Primer sequences for Fisher Maxima SYBR Green were derived from Primer Bank. Primer sequences for Bio-Rad SsoAdvanced Universal Probes Supermix were designed with Primer 3 Plus.
Constructing Knockdown Cell Lines
We used two independent short-hairpin oligonucleotides to knock down the expression of GSTP1 and one short-hairpin oligonucleotide to knock down the expression of CDH1 using previously described methods (Benjamin et al., 2013) . For generation of stable shRNA lines, lentiviral plasmids in the pLKO.1 backbone containing shRNA (Sigma) against human GSTP1 were transfected into HEK293T cells using Fugene (Roche). Lentivirus was collected from filtered cultured medium and used to infect the target cancer cell line with Polybrene. Target cells were selected over 3 days with 1 mg/ml puromycin. The short-hairpin sequences used for generation of the GSTP1 knockdown lines were: shGSTP1-1, CCGGCGCTGACTACAACCTGCTGGACTCGAGTCCAGC AGGTTGTAGTCAGCGTTTTTG; shGSTP1-2, CCGGCCTCACCCTGTACCAG TCCAACTCGAGTTGGACTGGTACAGGGTGAGGTTTTTG. The short-hairpin sequence used for generation of the CDH1 knockdown line was CCGGAGAAGGGTCTGTTCACGTATTCTCGAGAATACGTGAACAGA CCCTTCTTTTTTG.
The control shRNA was targeted against GFP with the target sequence GCAAGCTGACCCTGAAGTTCAT. Knockdown was confirmed by qPCR or western blotting.
Constructing FLAG-Tagged GSTP1 Cells GSTP1 cDNA (Dharmacon) was subcloned into the pENTR4-FLAG vector (Addgene). This entry vector was recombined via an attL-attR (LR) reaction into a pLenti CMV puro DEST vector (Addgene). For generation of the FLAGtagged GSTP1 line, the lentiviral plasmid containing FLAG-GSTP1 was transfected into HEK293T cells using Fugene (Roche). Lentivirus was collected from filtered cultured medium and used to infect the target cancer cell line with Polybrene. Target cells were selected over 3 days with 1 mg/ml puromycin.
Cellular Phenotype Studies
Cell proliferation, serum-free cell survival, and migration assays were performed in a manner similar to previously described assays (Benjamin et al., 2013 (Benjamin et al., , 2015 . More details are provided in Supplemental Experimental Procedures.
Tumor Xenograft Studies
Human tumor xenografts were established by transplanting cancer cells ectopically into the flank of C.B17 severe combined immunodeficiency (SCID) mice (Taconic Farms) as previously described (Nomura et al., 2010) . In brief, cells were washed twice with PBS, trypsinized, and harvested in serum-containing medium. Harvested cells were washed twice with serum-free medium and resuspended at a concentration of 2.0 3 10 4 cells/ml, and 100 ml was injected.
Tumors were measured every 2 days with calipers. Animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committees of the University of California, Berkeley.
Metabolomic Profiling of Cancer Cells
Metabolomic analyses were conducted using previously described methods (Benjamin et al., 2013 (Benjamin et al., , 2015 Long et al., 2011; Mulvihill et al., 2014) . More details are provided in Supplemental Experimental Procedures.
Lactic Acid Secretion
Lactic acid secretion from L-15 medium was measured by collecting medium and performing a colorimetric lactic acid assay using a kit purchased from Abcam in accordance with the manufacturer's protocol.
Glucose Consumption
Glucose consumption from RPMI medium was measured by collecting medium and performing a colorimetric glucose assay using a kit purchased from Abcam following the manufacturer's protocol.
Western Blotting E-cadherin antibody was obtained from BD Biosciences. Vimentin antibody was obtained from Sigma. Antibodies to cyclophilin, GSTP1, b-actin, phospho-AMPK a (Thr172), AMPK a, phospho-ACC (Ser79), ACC, phospho-S6, total S6, phospho-JNK (Thr183/Tyr185), JNK, and GAPDH were obtained from Cell Signaling Technology. FLAG antibody was obtained from Cayman Chemicals. Cells were lysed in lysis buffer (CST) containing both protease and phosphatase inhibitors. Proteins were resolved by electrophoresis on 4%-15% Tris-glycine precast Mini-PROTEAN TGX gel (Bio-Rad) and transferred to nitrocellulose membranes using the iBlot system (Invitrogen). Blots were blocked with 5% nonfat milk in Tris-buffered saline containing Tween 20 (TBST) solution for 1 hr at room temperature, washed in TBST, and probed with primary antibody diluted in recommended diluent per manufacturer overnight at 4 C. Following washes with TBST, the blots were incubated in the dark with an IR-linked secondary antibody at room temperature for 1 hr. Blots were visualized using an Odyssey Li-Cor scanner after additional washes.
Anti-FLAG Pulldown Studies
Pulldown studies were performed used Anti-FLAG M2 magnetic beads (Sigma) according to the manufacturer's protocol. FLAG-tagged GSTP1-overexpressing and GFP-overexpressing control cells were lysed in lysis buffer (CST), and 500 mg of lysate was incubated with 32 ml of anti-FLAG magnetic beads for 2 hr at 4 C. Beads were collected and washed three times with Tris-buffered saline before elution with 4% SDS (w/v) in 120 mM Tris-HCl. Samples were heated to 95 C for 3 min. Eluent was subsequently prepared for proteomic profiling with a shotgun proteomic analysis protocol as described below.
Shotgun Proteomic Profiling of Anti-FLAG Pulldown Pulldown products were precipitated in 20% trichloroacetic acid at À80 C overnight and centrifuged at 10,000 3 g at 4 C for 10 min to pellet protein. Pelleted proteins were washed three times with 8 M urea in PBS. After solubilization, 30 ml of 0.2% ProteaseMAX Surfactant (Promega) was added and the resulting mixture was vortexed followed by the addition of 40 ml of 100 mM ammonium bicarbonate and 10 mM tris(2-carboxyethyl)phosphine (TCEP). After 30 min, 12.5 mM iodoacetamide was added and allowed to react for 30 min in the dark before adding 120 ml of PBS and 1.2 ml of 1% ProteaseMAX Surfactant. The protein solution was vortexed, and 0.5 mg/ml sequencing-grade trypsin (Promega) was added and allowed to react overnight at 37 C. The peptide solution was then centrifuged at 10,000 3 g before the supernatant was subsequently analyzed by LC-MS/MS.
GAPDH Activity Assay GAPDH activity was measured using a colorimetric kit purchased from BioVision and performed according to the manufacturer's protocol. Active human GSTP1 and active human GAPDH full-length proteins were purchased from Abcam. Proteins were co-incubated at 37 C for 1 hr before GAPDH activity was measured using the kit.
Oxidative Stress
Oxidative stress was measured using CellROX Green Reagent (Invitrogen) according to the manufacturer's protocol.
Cysteine and Lysine Reactivity Profiling
Cysteine and lysine reactivity profiling was performed based on an adapted method that has been previously described (Medina-Cleghorn et al., 2015; Weerapana et al., 2010) . Tryptic digests for proteomic profiling were analyzed using a Thermo LTQ-XL and quantified by spectral counting using previously described methods (Nomura et al., 2010) . More details are provided in Supplemental Experimental Procedures.
GSTP1 Activity Assay
The IC 50 of LAS17 was determined using a GSTP1 activity assay. 1-Chloro-2,4-dinitrobenzene (CDNB) was incubated with 200 mM reduced glutathione and 1 mg of active GSTP1 protein with 100, 10, 1, 0.1, 0.01, 0.001, and 0 mM LAS17. GSTP1 catalyzes the conjugation of glutathione to CDNB, generating the reaction product glutathione-DNB conjugate, which absorbs at 340 nm. The rate of increase in the absorption of the product is proportional to GSTP1 activity and was used to measure GSTP1 activity.
In Vitro Labeling of GSTP1 with LAS17 50 mg of protein was incubated with 5 mM LAS17 for 30 min at room temperature. Following probe labeling, 25 mM rhodamine-azide, 1 mM TCEP, 100 mM tris(benzyltriazoylmethyl)amine, and 1 mM Cu(II)SO 4 were added and incubated for 1 hr at room temperature. Laemmli sample buffer was added, heated to 95 C for 5 min, and cooled to room temperature. Samples were loaded onto an SDS-PAGE gel and imaged by in-gel fluorescence using a Typhoon flatbed scanner. 
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